Efficacy And Safety Of Combination Induction Therapy With Guselkumab

Pdf Comparative Efficacy And Safety Of Antibody Induction Therapy For Are you looking for a new treatment option for ulcerative colitis? read this study to learn about the efficacy and safety of a combination therapy with guselkumab and golimumab, two biologic drugs that target different pathways of inflammation. find out how this therapy performed compared to golimumab alone in a randomized, double blind, active controlled trial with participants who had. Op36 efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis: results through week 12 of a phase 2a randomized, double blind, active controlled, parallel group, multicenter, proof of concept study.

Efficacy And Safety Of Combination Induction Therapy With Guselkumab Guselkumab is an antagonist of the p19 subunit of il 23 that is approved to treat plaque psoriasis. golimumab is an antagonist of tnfa and is approved for the treatment of ulcerative colitis. 1 the phase 2a vega study evaluated the safety and efficacy of induction therapy with guselkumab plus golimumab vs monotherapy with guselkumab or goli mumab in adults with moderately to severely active. While this study was being conducted, guselkumab efficacy in uc was demonstrated in a phase 2a, proof of concept, double blind study of guselkumab monotherapy and combination therapy with the tnf α antagonist, golimumab, in patients with moderately to severely active uc who were naïve to tnf α antagonists and had an inadequate response intolerance to corticosteroids or immunosuppressants. The phase 2a vega study evaluated the safety and efficacy of combination induction therapy with guselkumab plus golimumab (gol) vs monotherapy with guselkumab or gol in adults with moderately to. Vega was a randomized, double blind, active controlled, parallel group, global multicenter phase 2a proof of concept study evaluating the efficacy and safety of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab monotherapy for maintenance, in patients with moderately to severely active uc as defined by a mayo score of 6 to 12 inclusive and an.